ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion

ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more about IBRX stock here.

Read Full Article →